Skip to search.

Breaking News Visit Yahoo! News for the latest.

×Close this window

 Dow Up0.06% Nasdaq Down0.01%

Celgene Corporation (CELG)

-NasdaqGS

122.58 Down 1.06(0.86%) May 24, 4:00PM EDT|After Hours : 122.58 0.00 (0.00%) May 24, 4:20PM EDT

Add to Portfolio
ProfileGet Profile for:
Celgene Corporation
86 Morris Avenue
Summit, NJ 07901
United States - Map
Phone: 908-673-9000
Fax: 908-673-9001
Website: http://www.celgene.com

Details 
Index Membership:Nasdaq 100
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:4,700

Business Summary 

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and immune-inflammatory related diseases in the United States, Europe, and other countries. Its commercial stage products include REVLIMID, an oral immunomodulatory drug to treat patients with multiple myeloma and transfusion-dependent anemia; VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk myelodysplastic syndromes (MDS), as well as acute myeloid leukemia (AML); ABRAXANE, a solvent-free chemotherapy treatment option for metastatic breast cancer; and THALOMID for multiple myeloma and the cutaneous manifestations of erythema nodosum leprosum. The company’s commercial stage products also comprise ISTODAX to treat cutaneous T-cell lymphoma; POMALYST for the multiple myeloma and myelofibrosis treatment; and FOCALIN, FOCALIN XR, and RITALIN LA products. Its pre clinical and clinical stage products consist of CC-11050, an anti-inflammatory compound; CC-220, an anti-inflammatory product; cellular therapies, such as PDA-001 and PDA-002; CC-486 that is in Phase III trials to treat MDS and AML, as well as in a Phase I trials for the treatment of solid tumor indications; and sotatercept and ACE-536, which are in Phase II trials to treat anemia in patients with blood disorders. The company’s pre clinical and clinical stage products also include CC-223, a dual TORK inhibitor; CC-292, a BTK inhibitor; CC-115, a dual TORK/DNA PK inhibitor; CC-122, a pleiotropic pathway modulator; and EPZ-5676, a DOT1L inhibitor. It has strategic collaborations with bluebird bio, Inc. to discover, develop, and commercialize gene therapies in oncology; FORMA Therapeutics Holdings to discover, develop, and commercialize drug candidates to regulate protein homeostasis; and Concert Pharmaceuticals, Inc. to develop deuterium-modified compounds for cancer and inflammation. The company was founded in 1980 and is headquartered in Summit, New Jersey.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Celgene Corporation

Corporate Governance 
Celgene Corporation’s ISS Governance QuickScore as of May 1, 2013 is 5. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 1; Compensation: 8.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. Robert J. Hugin MBA, 58
Chairman, Chief Exec. Officer, Pres and Chairman of Exec. Committee
4.58M1.10M
Ms. Jacqualyn A. Fouse Ph.D., 52
Chief Financial Officer, Chief Accounting Officer and Exec. VP
1.25M0.00
Mr. Perry A. Karsen , 58
Chief Operations Officer and Exec. VP
1.87M0.00
Dr. Thomas O. Daniel M.D., 59
Exec. VP and Pres of Research & Early Devel.
1.58M0.00
Mr. Mark J. Alles , 54
Chief Commercial Officer, Global Head of Hematology & Oncology and Exec. VP
1.43M0.00
Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders